RxDoctor Payments Data

Amol Bapat, MD

Interventional Cardiology · Marietta, GANPI 1316937378

Payments from drug & device makers

$4,351in general payments, 2019–2025

Across 124 payments — averaging $35.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$1000
  • Boehringer Ingelheim$426
  • Novartis$411
  • Johnson & Johnson$336
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$250
  • Abbott$244
  • plus $2K from 16 others

What the payments were for

  • Food & beverage$4,351100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,351 in reported general payments places this provider in the 25th percentile of 218 interventional cardiology providers in Georgia.

See all interventional cardiology providers in Georgia

Medicare billing

Part B allowed, 2024
$243,150
Medicare patients
1,658
Services billed
7,940

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban222$254,720
JardianceEmpagliflozin33$38,271
XareltoRivaroxaban30$32,064
EntrestoSacubitril/Valsartan14$26,131
Atorvastatin Calcium303$3,108
Rosuvastatin Calcium233$2,577
Nebivolol Hcl34$2,511
Metoprolol Succinate163$2,447
Ezetimibe128$2,235
Ranolazine ErRanolazine17$1,745
ClopidogrelClopidogrel Bisulfate88$1,354
Carvedilol122$1,004
Diltiazem 24hr Er (Cd)Diltiazem Hcl15$938
Potassium Chloride65$806
Valsartan22$733

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$216$254,720222 claims
Boehringer IngelheimJardiance$426$38,27133 claims
Johnson & JohnsonXarelto$336$32,06430 claims
NovartisEntresto$411$26,13114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 218 interventional cardiology providers in Georgia.

Other interventional cardiology in Marietta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →